TRISENOX (arsenic trioxide) and potential medication errors: DHPC from Teva Pharmaceuticals

Drug Safety Alert, Drug Safety Updates, EMA-European Medicines Agency, Global Safety Alerts, HPRA-Ireland, Medication Errors, Medicinal Product Updates, Pharmacovigilance, Safety Communications, , ,

Arsenic trioxide is a chemotherapeutic medication used in the treatment of newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) and relapsed/refractory APL characterized by the presence of leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene. The initial approved formulation available in market for arsenic trioxide is 1 mg/ml single-use 10 ml of glass ampoule (This formulation comprises 10 mg of…

Read More

Potential medication error and unintentional overdose associated with methotrexate use

EMA-European Medicines Agency, Global Safety Alerts, Medicinal Product Updates, MHRA-United Kingdom, Pharmacovigilance, Safety Communications, , ,

Methotrexate is an immunosuppressant medication used in the treatment of autoimmune diseases and some type of cancers. It acts by competitively inhibiting the dihydrofolate reductase (DHFR), a key enzyme involved in the synthesis of DNA, RNA, thymidylates, and proteins. Different regulatory bodies issued alerts on the safety concerns of medication errors and fatal overdose occurrences…

Read More

A new drug safety signal from Uppsala Monitoring Centre (UMC) Lack of drug dose titration (Medication error) during treatment with clozapine

A New Drug Safety Signal from Uppsala Monitoring Centre (UMC): Lack of drug dose titration (Medication error) during treatment with clozapine

Drug Safety Signal, Global Safety Alerts, Medicinal Product Updates, Pharmacovigilance, WHO, , , ,

A new drug safety signal identified by the Uppsala Monitoring Centre (UMC), Sweden a WHO Collaborating Centre for international service and scientific research within the field of pharmacovigilance. This safety signal is identified from the VigiBase, a global drug safety database maintained by UMC on behalf of WHO and published in the WHO Pharmaceuticals newsletter…

Read More

error: Content is protected !!